Vivici and The Every Company Weigh 4-Million-Liter Precision Fermentation Plant in the UAE

Vivici Every Company UAE: Two of the precision fermentation sector’s most closely watched names are weighing a substantial new footprint in the Middle East. Vivici, the Indian alt-protein startup backed by a joint venture between Titan Company and Premji Invest, is exploring plans for a 4-million-liter fermentation facility in the United Arab Emirates alongside The Every Company, the US-based food technology firm best known for its animal-free whey protein. The proposed site, which is still in early evaluation stages, would rank among the largest single-tenant precision fermentation plants publicly discussed to date and would mark the first major overseas manufacturing venture for either partner.

The UAE has spent the past three years positioning itself as a regional hub for alternative protein production, leaning on relatively cheap energy, established food-grade logistics, and government-backed food security programs that explicitly encourage novel protein sources. For Vivici and The Every Company, a facility of that scale in the Gulf would address two persistent bottlenecks in the category: the lack of contracted fermentation capacity outside a handful of European and North American players, and the high cost of scaling animal-free proteins to price parity with their dairy counterparts.

Vivici Every Company UAE: Why a UAE facility, and why now

Pricing remains the single biggest barrier to mainstream adoption of animal-free proteins. Dairy proteins in particular have benefited from decades of agricultural optimisation, meaning that any novel ingredient must clear aggressive cost targets to win share with food and beverage manufacturers. Precision fermentation has steadily improved on that front as production volumes have grown, but the category still depends on a small number of large fermentation vessels operated by a handful of contract manufacturers.

Locating in the UAE offers several practical advantages. Industrial electricity prices in the Emirates tend to run below European benchmarks, which matters for energy-hungry aerobic fermentation runs. The country also offers well-established cold-chain and food export corridors into South Asia, the wider Gulf Cooperation Council region, and parts of Africa. For Vivici specifically, a UAE base would sit roughly halfway between its Indian consumer market and the European buyers it has signalled interest in serving, while keeping it close to the protein-supply gaps that have shaped the country’s food security policy.

Government policy direction has reinforced those commercial considerations. Emirati authorities have, over the past two years, explicitly named alternative proteins among the priority sectors under national food security and industrial diversification strategies. That policy framing tends to translate into practical support for greenfield food manufacturing investment, ranging from expedited permitting to land allocations in dedicated industrial clusters.

What Vivici brings to the partnership

Vivici has moved quickly since it was established as a Titan Company and Premji Invest joint venture to position itself as a serious player in the Indian alternative protein space. The startup has focused on bringing globally developed fermentation and bioprocessing technologies into the Indian market, working with international partners to produce animal-free dairy proteins at scale for domestic food and beverage customers.

The partnership with The Every Company would extend that model beyond India’s borders. Rather than building every capability in a new geography, Vivici has consistently pursued a hub-and-spoke approach, anchoring itself in one large-scale manufacturing location and serving adjacent markets through distribution and customer partnerships. A 4-million-liter UAE plant would effectively anchor a Middle East spoke, leaving the company free to channel Indian demand through partnerships closer to home.

What The Every Company contributes

The Every Company has spent several years developing its proprietary precision fermentation process for producing animal-free whey protein, an ingredient with direct application in sports nutrition, infant formula, and a wide range of mainstream dairy-adjacent products. The company has talked openly about the need for second-source fermentation capacity as customer demand has grown, particularly among large multinational brands that require redundant supply chains.

A UAE plant would give The Every Company geographic diversification in a region where it does not currently operate its own assets, and would place capacity closer to Asian and Middle Eastern buyers currently being served by transatlantic shipments. It would also test the company’s ability to replicate its production process in a different regulatory and utility environment, which is a meaningful proof point for any fermentation business trying to convince multinational customers to reformulate around its ingredient.

The 4-million-liter figure in context

Precision fermentation capacity is typically described in terms of annual fermenter volume, with a single large vessel often holding tens of thousands of liters. A facility rated at 4 million liters of fermentation capacity per year would meaningfully exceed the publicly disclosed output of most individual precision fermentation plants operated by single companies, and would place the proposed UAE site among the larger dedicated capacity pools in the global alternative protein infrastructure.

For comparison, the broader alt-protein manufacturing base remains dominated by contract development and manufacturing organisations that also serve pharmaceutical and industrial biotech customers. Dedicated food-grade fermentation capacity is significantly smaller in aggregate, which is one of the structural reasons that alt-protein ingredients continue to trade at a premium to their conventional counterparts. New builds of this scale, particularly outside the traditional US and European production clusters, have the potential to shift that cost curve if they run consistently at high utilisation.

Open questions around the project

Several details about the proposed venture remain undefined. Neither company has confirmed a timeline for breaking ground, a specific Emirate for the site, or a definitive cost figure for the facility. Early-stage precision fermentation plants of comparable scale have, in other cases, required hundreds of millions of dollars in combined equity, debt, and offtake-linked financing, but the partners have not signalled how the UAE project would be capitalised or how the equity would be split between Vivici and The Every Company.

There is also no confirmation yet of long-term offtake agreements with named customers, although both companies have existing commercial relationships with consumer brands that could anchor demand for a portion of the plant’s output. The choice of host Emirate could also have a material effect on operating economics, given differences in utility pricing, water availability, and proximity to export infrastructure across the country’s industrial clusters.

Why this matters for the alt-protein category

The alt-protein sector has spent the past several years moving from a phase dominated by laboratory breakthroughs into one defined by manufacturing scale-up. Investors and large food manufacturers have consistently pointed to the gap between pilot-scale success and reliable, cost-competitive commercial supply as the category’s central challenge. New fermentation capacity, particularly in geographies that have not historically hosted precision fermentation at scale, is one of the clearest signals that the industry is moving toward the production-led phase of its development.

A successful UAE build would also have a second-order effect on the regional alternative protein ecosystem. Large fermentation facilities tend to attract downstream ingredient formulators, co-manufacturers, and quality testing services, which can in turn encourage smaller domestic startups to commercialise products that depend on locally available fermentation capacity. That kind of cluster effect has been visible in parts of the US Midwest and in Singapore, and Emirati policymakers have signalled interest in cultivating a similar dynamic around food and feed biotechnology.

Outlook

For now, the Vivici and The Every Company announcement is best read as an exploration of strategic intent rather than a confirmed build. The 4-million-liter target is large enough to be commercially meaningful, and the choice of the UAE reflects both the operating economics of the Gulf and the policy direction of Emirati food security planners. If the partners move from feasibility work to a final investment decision over the coming quarters, it would represent one of the more significant single commitments to dedicated alt-protein fermentation capacity announced outside North America and Europe in recent years, and would underline how seriously precision fermentation is now being treated as a global industrial category rather than a Western innovation story.